Garrison Point Advisors LLC boosted its position in Bristol-Myers Squibb Co (NYSE:BMY) by 53.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,942 shares of the biopharmaceutical company’s stock after buying an additional 6,565 shares during the period. Garrison Point Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,216,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. BlackRock Inc. lifted its position in Bristol-Myers Squibb by 6.7% in the second quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock valued at $5,206,108,000 after purchasing an additional 7,178,698 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Bristol-Myers Squibb by 42.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 12,749,545 shares of the biopharmaceutical company’s stock worth $578,192,000 after buying an additional 3,816,247 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Bristol-Myers Squibb by 1.9% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,386,695 shares of the biopharmaceutical company’s stock valued at $374,579,000 after buying an additional 134,804 shares during the period. California Public Employees Retirement System lifted its holdings in shares of Bristol-Myers Squibb by 16.2% in the 3rd quarter. California Public Employees Retirement System now owns 6,295,047 shares of the biopharmaceutical company’s stock valued at $319,222,000 after buying an additional 876,371 shares during the period. Finally, Eaton Vance Management lifted its holdings in shares of Bristol-Myers Squibb by 108.3% in the 2nd quarter. Eaton Vance Management now owns 5,195,648 shares of the biopharmaceutical company’s stock valued at $235,623,000 after buying an additional 2,701,008 shares during the period. Hedge funds and other institutional investors own 83.35% of the company’s stock.

In related news, SVP John E. Elicker sold 15,000 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the sale, the senior vice president now directly owns 74,471 shares of the company’s stock, valued at approximately $4,219,526.86. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Louis S. Schmukler sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the completion of the sale, the insider now directly owns 31,963 shares in the company, valued at $1,807,827.28. The disclosure for this sale can be found here. Insiders own 0.13% of the company’s stock.

A number of research analysts recently weighed in on the company. Citigroup raised Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 price objective on the stock in a report on Monday, January 6th. ValuEngine raised Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a report on Tuesday, November 19th. Bank of America assumed coverage on shares of Bristol-Myers Squibb in a research report on Wednesday, October 16th. They set a “buy” rating and a $60.00 target price on the stock. Wolfe Research set a $66.00 target price on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Friday, November 1st. Finally, Mizuho assumed coverage on shares of Bristol-Myers Squibb in a research note on Monday, November 25th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have assigned a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Buy” and an average target price of $61.69.

NYSE BMY traded down $2.91 during mid-day trading on Friday, hitting $63.96. The stock had a trading volume of 17,213,027 shares, compared to its average volume of 12,153,140. The company has a 50 day simple moving average of $64.02 and a 200 day simple moving average of $53.87. The company has a market cap of $109.86 billion, a price-to-earnings ratio of 18.43, a P/E/G ratio of 0.81 and a beta of 0.73. Bristol-Myers Squibb Co has a 52-week low of $42.48 and a 52-week high of $68.34. The company has a quick ratio of 3.72, a current ratio of 3.83 and a debt-to-equity ratio of 1.37.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the Zacks’ consensus estimate of $1.06 by $0.11. The company had revenue of $6.01 billion for the quarter, compared to the consensus estimate of $5.89 billion. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. Bristol-Myers Squibb’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.09 earnings per share. As a group, equities analysts anticipate that Bristol-Myers Squibb Co will post 4.34 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be paid a dividend of $0.45 per share. This represents a $1.80 annualized dividend and a dividend yield of 2.81%. The ex-dividend date is Thursday, January 2nd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. Bristol-Myers Squibb’s payout ratio is 45.23%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: The limitations of an equal weight rating

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.